Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

JAMA Dermatol. 2016 Mar;152(3):348-50. doi: 10.1001/jamadermatol.2015.3405.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biopsy
  • Drug Resistance
  • Drug Substitution
  • Follow-Up Studies
  • Humans
  • Male
  • Phosphodiesterase 4 Inhibitors / therapeutic use*
  • Pityriasis Rubra Pilaris / diagnosis
  • Pityriasis Rubra Pilaris / drug therapy*
  • Pityriasis Rubra Pilaris / pathology
  • Remission Induction
  • Skin / drug effects
  • Skin / pathology
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Phosphodiesterase 4 Inhibitors
  • Thalidomide
  • apremilast